This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effects of any platinum infusion duration to prevent hearing loss and/or tinnitus in children with cancer treated with platinum‐based therapy (i.e. including cisplatin, carboplatin and/or oxaliplatin) when compared to another infusion duration. We will also assess possible effects of these infusion durations on anti‐tumour efficacy (i.e. tumour response and survival) of platinum‐based therapy, on adverse effects other than hearing loss and/or tinnitus and on quality of life.